The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD-L1.

Abstract in brief

• Sunitinib plays a beneficial role in tumor immune surveillance by increasing anti-tumor immunity through the regulation of PDL1 degradation, which is linked to better responses in cancer treatments.
• The drug enhances immune system activity by promoting tumor-infiltrating lymphocytes and works synergistically with immune checkpoint inhibitors like CTLA4 antibodies, especially in melanoma and lung cancer models.
• Clinically, higher PDL1 levels and lower p62 levels in tumors are associated with better responses to anti-PD1 therapy, suggesting that combining Sunitinib with other immunotherapies could offer a new effective treatment strategy.]